Please login to the form below

Not currently logged in
Email:
Password:

Scott Whitcup joins Questcor’s board of directors

Allergan’s chief scientific officer to help expand Acthar’s use to treat autoimmune conditions

Scott Whitcup - Questcor PharmaceuticalsScott Whitcup, executive VP of R&D and chief scientific officer at Amgen, has joined the board of directors at Questcor Pharmaceuticals.

The company said his experience in commericialising Botox as a treatment for chronic migraine, upper limb spasticity and neurogenic urologic conditions would be beneficial in Questcor's efforts to expand the uses of its own Acthar Gel brand to treat autoimmune conditions.

“The growth strategies and product manufacturing for Acthar and Botox have some interesting parallels,” said Questcor's chair, Virgil Thompson.

Acthar is currently approved in the US in several indications, including infantile spasms; exacerbations of multiple sclerosis in adults; nephrotic syndrome; and several rheumatic disorders including collagen diseases; dermatologic diseases and ophthalmic diseases.

Whitcup joined Allergan in 2000, becoming executive VP of R&D in 2004 and chief scientific officer in 2009.

Other products he has helped bring to market at Allergan include Lumigan, Restasis and Latisse.

Prior to joining Allergan Whitcup served as clinical director at the National Institutes of Health's National Eye Institute, where he help develop new therapies for ophthalmic diseases

22nd February 2012

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Novasecta

We are a specialist strategy consulting firm for pharmaceutical and biotech companies. We help our clients to achieve significant performance...

Latest intelligence

Brain power: fresh approaches to Alzheimer’s drug discovery
New alliances are learning from past mistakes and breaking down research barriers...
Genomics integration: can the NHS rise to the challenge?
Experts gather to discuss the UK’s genomic landscape...
London
“Brexit has been a catalyst for UK clinical research... it’s turbocharged change”
The UK clinical trials environment has been transformed in recent years – but can it really buck Brexit’s risks and uncertainties?...

Infographics